← Human Trials & Peer-Reviewed Studies
Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency.
Plain-language guide to PMID 12699438 (2003): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 97 patients.
Key Facts
- PMID
- 12699438
- Journal
- Clinical endocrinology
- Year
- 2003
- Study type
- Randomized Controlled Trial
- Authors
- Svensson J et al. (14 authors)
- DOI
- 10.1046/j.1365-2265.2003.01754.x
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Little is known of the usefulness of GH secretagogues (GHSs) in GH-deficient (GHD) adults.
The objective of this study was to determine the number of responders to treatment with NN703 in GHD adults.
Who Took Part
According to the abstract, 97 patients were involved.
PubMed indexes the participants as adults and middle-aged adults, both men and women.
Ninety-seven GHD adults were included.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and multicenter.
Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.
Neither the patients nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.
The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.
Running at several centres spread the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study over different clinics and patient groups.
A multicentre, randomized, double-blind, and placebo-controlled study.
What Was Measured
Topics PubMed links to this paper include Area Under Curve, Blood Pressure, Dipeptides, Fatty Acids, Nonesterified, Human Growth Hormone, Insulin-Like Growth Factor Binding Protein 3 and Insulin-Like Growth Factor I.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 97 patients.
Its findings take up roughly 11 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2003 (Clinical endocrinology), a journal based in England.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.